[CAS NO. 1630760-75-6]  BRD9500

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1630760-75-6]

Catalog
HY-136350
Brand
MCE
CAS
1630760-75-6

DESCRIPTION [1630760-75-6]

Overview

MDL-
Molecular Weight291.32
Molecular FormulaC15H18FN3O2
SMILESO=C1C[C@@H](C)C(C2=CC=C(N3CCOCC3)C(F)=C2)=NN1

For research use only. We do not sell to patients.

Summary

BRD9500 is an orally active phosphodiesterases 3 ( PDE3 ) inhibitor with IC 50 s of 10 and 27 nM for PDE3A and PDE3B , respectively. Antitumor activity [1] .


IC50 & Target

PDE3A

10 nM (IC 50 )

PDE3B

27 nM (IC 50 )


In Vitro

BRD9500 is a DNMDP analog. DNMDP potently and selectively inhibits PDE3A and PDE3B and kills cancer cells by inducing PDE3A/B interactions with SFLN12 [1] .
BRD9500 exhibits an EC 50 of 1 nM for SK-MEL-3 melanoma cell line viability [1] .
BRD9500 exhibits an EC 50 of 1.6 nM for HeLa viability [1] .
BRD9500 (10 μM; 8 hours) stabilizes the PDE3A-SLFN12 interaction in HeLa cells [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis [1]

Cell Line: HeLa cells
Concentration: 10 μM
Incubation Time: 8 hours
Result: SLFN12 coimmunoprecipitation was analyzed by immunoblotting with an anti-V5 antibody to detect the SLFN12-V5 fusion protein. The SLFN12-V5 was clearly detected with the anti-V5 antibody.

In Vivo

BRD9500 (10, 20, and 50 mg/kg; orally) inhibits SK-MEL-3 melanoma growth in mice [1] .
BRD9500 shows high plasma levels in mice after iv (1 mg/kg) as well as po (2 mg/kg) dosing over eight hours making it a valuable candidate for in vivo xenograft testing [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female NMRI nude mice bearing SK-MEL-3 melanoma cells tumor xenografts [1]
Dosage: 10, 20, and 50 mg/kg
Administration: Orally at 10 and 20 mg/kg twice daily (2QD) and at 50 mg/kg once per day (QD).
Result: Achieved the strongest antitumor activity at 50 mg/kg. All treatments were well tolerated without critical body weight loss or toxicities.

Appearance

Solid


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL ( 171.63 mM ; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.4327 mL 17.1633 mL 34.3265 mL
5 mM 0.6865 mL 3.4327 mL 6.8653 mL
10 mM 0.3433 mL 1.7163 mL 3.4327 mL
* Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

    Solubility: ≥ 2.5 mg/mL (8.58 mM); Clear solution

  • 2.

    Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (8.58 mM); Clear solution

  • 3.

    Add each solvent one by one: 10% DMSO >> 90% corn oil

    Solubility: ≥ 2.5 mg/mL (8.58 mM); Clear solution

* All of the co-solvents are available by MCE.